[Ip-health] The Economic Times: Roche sues Biocon, Mylan, DCGI over breast cancer drug
shailly.gupta at geneva.msf.org
Thu Feb 6 22:12:07 PST 2014
Roche sues Biocon, Mylan, DCGI over breast cancer drug
NEW DELHI: The Indian arm of Swiss pharma major Roche, which unexpectedly
gave up its patent on it s $6 billion breast cancer drug Herceptin
(Trastuzumab) in India last year, has sued Bangalore based Biocon and US
generic giant Mylan Inc in Delhi High Court (HC) for launching world's first
biosimilar version of the original drug in India.
It has also sued the Drug Controller General of India for giving permission
for such a launch. The Delhi High Court has restrained Mylan and Biocon
from "relying upon" or "referring to Herceptin" or any data relating to it
for selling or promoting their brands Canmab (Biocon)and Hertaz (Mylan) till
the next hearing, according to an order reviewed by ET. Trastumab was being
considered for a compulsory license, but Roche pre-empted the move by not
renewing the patent here.
Roche has told the court that the drugs of Biocon and Mylan are being
misrepresented as 'biosimilar Trastuzumab' and 'biosimilar version of
Herceptin' without following the 'due process in accordance with the
guidelines on similar biologics' for getting approvals in India. The Swiss
company argues that there is no public record available, in the clinical
trial registry India (CTRI) or elsewhere to show that these firms actually
conducted phase-I or phase-II clinical trials for the drug.
Roche further contests that guidelines on similar biologics were only issued
in 2012, which laid down 'a detailed and structured process for comparison
of biosimilar with the original product and "all the applications for
manufacturing and marketing authorization" of biosimilars have to follow
that path before getting an approval. Roche also claims that DCGI has
approved Biocon's "protocol and design study for testing" related to the
proposed drug even before its own regulatory guidelines were firmed up.
"As per the annual report for the year 2012 of the defendant No 2 (Biocon),
in June 2012 much before the guidelines became effective, the defendant No 2
was already conducting Phase III clinical trials (for the drug candidate)"
Roche has pleaded, according to a copy of the Delhi HC order.
Roche has cast doubts in its submission saying the Indian drug regulator's
approval for biosimilars couldn't have come about in 'such a short period'
when its 'prescribed procedure' in the guideline is so long.
Three months after Roche announced that it would no longer pursue a patent
on breast cancer drug Herceptin in India, Biocon in October last year got an
approval for making the drug from the central drug regulator.
The journey of this blockbuster drug, which earns its parent company over $6
billion in annual sales globally, has been particularly intriguing in India
as it was the first drug candidate, which was being considered for grant of
a compulsory license by the government under section 92 of Indian Patents
Act. The case for grant of compulsory license was buried after Roche in
August unexpectedly dropped claims for a patent on drug by not applying for
a renewal of its existing patent in India.
While Roche and Mylan couldn't be reached for their comment immediately, a
Biocon spokesperson refused to comment saying the company was not appraised
of the matter yet. Biocon has developed this biosimilar in partnership with
US generic giant Mylan and both launched their brands early this year with
Roche which markets Trastuzumab in India under the 'Herceptin', commands a
near monopoly in this market here. Roche had launched the drug at over 1
lakh per vial. However, following India's decision to grant its first
compulsory licence on liver cancer drug Sorafenib (Nexavar), Roche in March
2012 announced a cut of over 15% in the price of Herceptin per dose to
92,000. It also tied up with Indian drug maker Emcure Pharma, which started
offering the drug under brand Herclon at 72,000 per dose. While Roche, known
for aggressively defending its patents, it didn't give a specific reason for
dropping its patent on this drug here, sector analysts read this as a change
in its India strategy.
Patient groups, however, alleged that the company made such a move because
it was on weak ground with regards to this drug patent in India.
Advocacy and Communication Officer
MSF Access Campaign
K-30 First Floor, Jangpura Extension
New Delhi - 14
Please sign MSF's DR-TB Manifesto today:
More information about the Ip-health